Safety Concerns Halt Merck & Co’s Once-Weekly HIV Combination
Blow For Company’s HIV Strategy
Executive Summary
Merck & Co. is looking to compete in the burgeoning long-acting HIV market, but a safety halt to a Phase II trial could disrupt those plans.
You may also be interested in...
Gilead Trial Pause Adds To Merck & Co’s HIV Concerns
The partners are halting recruitment out of “an abundance of caution,” but Gilead could decide to exit the alliance if islatravir cannot shake off safety concerns.
Merck & Co./Gilead Team To Take On ViiV In Long-Term HIV Treatment
The companies hope the combination of islatravir and lenacapavir will result in best-in-class oral and injectable long-term HIV products. A PrEP combo is a longer-term goal.
Cambridge Vision Achieved, AstraZeneca Looks To Realize ‘Pipeline 2’ Ambitions
Having achieved a turnaround in its R&D and commercial fortunes, AstraZeneca’s hopes the opening of a new research center will herald its next wave of novel therapies.